Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol’s DTC Moratorium Will Affect Muraglitazar, Abatacept Launches

Executive Summary

Muraglitazar and abatacept are likely to be the first Bristol-Myers Squibb products significantly affected by the company's recent moratorium on direct-to-consumer advertising during a drug's first 12 months on the market

You may also be interested in...



DTC Limits Best Countered By Free Speech, Not Public Health, Arguments

Limits on direct-to-consumer advertising which have been proposed in pending drug safety legislation may best be defeated by constitutional, rather than public health, arguments, Jim Davidson, president of the public policy advisory firm Davidson & Company, said

DTC Limits Best Countered By Free Speech, Not Public Health, Arguments

Limits on direct-to-consumer advertising which have been proposed in pending drug safety legislation may best be defeated by constitutional, rather than public health, arguments, Jim Davidson, president of the public policy advisory firm Davidson & Company, said

Orencia Promos To Focus On Docs, Disease Awareness; No Branded DTC For Now

Professional education efforts will be the centerpiece of Bristol-Myers Squibb's late-February launch of the rheumatoid arthritis treatment Orencia (abatacept) under the company's voluntary direct-to-consumer advertising moratorium for new products

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS045949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel